Is Sutro Biopharma Stock a Good Investment?
Sutro Biopharma Investment Advice | STRO |
- Examine Sutro Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Sutro Biopharma's leadership team and their track record. Good management can help Sutro Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Sutro Biopharma's business and its evolving consumer preferences.
- Compare Sutro Biopharma's performance and market position to its competitors. Analyze how Sutro Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if Sutro Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Sutro Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Sutro Biopharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Sutro Biopharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Sutro Biopharma Stock
Researching Sutro Biopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 75.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.19. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sutro Biopharma has Price/Earnings To Growth (PEG) ratio of 0.12. The entity recorded a loss per share of 1.51. The firm had not issued any dividends in recent years.
To determine if Sutro Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sutro Biopharma's research are outlined below:
| Sutro Biopharma generated a negative expected return over the last 90 days | |
| Sutro Biopharma may become a speculative penny stock | |
| Sutro Biopharma has high historical volatility and very poor performance | |
| Sutro Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 153.73 M. Net Loss for the year was (106.79 M) with loss before overhead, payroll, taxes, and interest of (73.82 M). | |
| Sutro Biopharma currently holds about 225.64 M in cash with (111.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Sutro Biopharma has a poor financial position based on the latest SEC disclosures | |
| Roughly 75.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Shareholders in Sutro Biopharma have lost 86, as stock drops 18 percent this past week |
Sutro Biopharma Quarterly Cash And Short Term Investments |
|
Sutro Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sutro Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sutro Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Sutro Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Sutro Biopharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-05-07 | 2021-03-31 | -0.6 | -0.66 | -0.06 | 10 | ||
2022-05-09 | 2022-03-31 | -0.76 | -0.84 | -0.08 | 10 | ||
2019-08-14 | 2019-06-30 | -0.68 | -0.6 | 0.08 | 11 | ||
2023-08-10 | 2023-06-30 | -0.73 | -0.64 | 0.09 | 12 | ||
2022-08-08 | 2022-06-30 | -0.46 | -0.55 | -0.09 | 19 | ||
2019-11-08 | 2019-09-30 | -0.65 | -0.56 | 0.09 | 13 | ||
2022-02-28 | 2021-12-31 | -0.69 | -0.83 | -0.14 | 20 | ||
2020-05-11 | 2020-03-31 | -0.69 | -0.84 | -0.15 | 21 |
Know Sutro Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sutro Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sutro Biopharma backward and forwards among themselves. Sutro Biopharma's institutional investor refers to the entity that pools money to purchase Sutro Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Parkman Healthcare Partners Llc | 2024-12-31 | 1.7 M | Goldman Sachs Group Inc | 2024-12-31 | 1.7 M | State Street Corp | 2024-12-31 | 1.7 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.5 M | Nuveen Asset Management, Llc | 2024-09-30 | 1.2 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.1 M | Renaissance Technologies Corp | 2024-12-31 | 1 M | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 859.4 K | Arrowstreet Capital Limited Partnership | 2024-09-30 | 737.7 K | Blackrock Inc | 2024-12-31 | 7.6 M | Suvretta Capital Management, Llc | 2024-12-31 | 7.5 M |
Sutro Biopharma's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 136.06 M.Market Cap |
|
Sutro Biopharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.26) | (0.27) | |
| Return On Capital Employed | (0.21) | (0.22) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (0.82) | (0.78) |
Determining Sutro Biopharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Sutro Biopharma is a good buy. For example, gross profit margin measures Sutro Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sutro Biopharma's profitability and make more informed investment decisions.
Evaluate Sutro Biopharma's management efficiency
Sutro Biopharma has return on total asset (ROA) of (0.184) % which means that it has lost $0.184 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1089) %, meaning that it created substantial loss on money invested by shareholders. Sutro Biopharma's management efficiency ratios could be used to measure how well Sutro Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of February 2025, Return On Tangible Assets is likely to drop to -0.27. In addition to that, Return On Capital Employed is likely to drop to -0.22. At this time, Sutro Biopharma's Total Current Assets are very stable compared to the past year. As of the 27th of February 2025, Debt To Assets is likely to grow to 0.13, while Total Assets are likely to drop about 289.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.24 | 2.10 | |
| Tangible Book Value Per Share | 2.24 | 2.10 | |
| Enterprise Value Over EBITDA | (3.77) | (3.96) | |
| Price Book Value Ratio | 1.55 | 0.93 | |
| Enterprise Value Multiple | (3.77) | (3.96) | |
| Price Fair Value | 1.55 | 0.93 | |
| Enterprise Value | 200.2 M | 231.7 M |
The strategic initiatives led by Sutro Biopharma's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 1.151 |
Basic technical analysis of Sutro Stock
As of the 27th of February, Sutro Biopharma has the Coefficient Of Variation of (673.42), risk adjusted performance of (0.10), and Variance of 20.66. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sutro Biopharma, as well as the relationship between them.Sutro Biopharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sutro Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sutro Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sutro Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sutro Biopharma's Outstanding Corporate Bonds
Sutro Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sutro Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sutro bonds can be classified according to their maturity, which is the date when Sutro Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Sutro Biopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Sutro Biopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | (0.67) | |||
| Mean Deviation | 3.35 | |||
| Coefficient Of Variation | (673.42) | |||
| Standard Deviation | 4.55 | |||
| Variance | 20.66 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.68) | |||
| Total Risk Alpha | (0.65) | |||
| Treynor Ratio | (0.68) | |||
| Maximum Drawdown | 20.35 | |||
| Value At Risk | (10.05) | |||
| Potential Upside | 4.89 | |||
| Skewness | (0.78) | |||
| Kurtosis | 1.63 |
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | (0.67) | |||
| Mean Deviation | 3.35 | |||
| Coefficient Of Variation | (673.42) | |||
| Standard Deviation | 4.55 | |||
| Variance | 20.66 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.68) | |||
| Total Risk Alpha | (0.65) | |||
| Treynor Ratio | (0.68) | |||
| Maximum Drawdown | 20.35 | |||
| Value At Risk | (10.05) | |||
| Potential Upside | 4.89 | |||
| Skewness | (0.78) | |||
| Kurtosis | 1.63 |
Consider Sutro Biopharma's intraday indicators
Sutro Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sutro Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 46453.23 | |||
| Daily Balance Of Power | (0.29) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 1.64 | |||
| Day Typical Price | 1.63 | |||
| Price Action Indicator | (0.05) | |||
| Period Momentum Indicator | (0.04) | |||
| Relative Strength Index | 44.23 |
Sutro Stock media impact
Far too much social signal, news, headlines, and media speculation about Sutro Biopharma that are available to investors today. That information is available publicly through Sutro media outlets and privately through word of mouth or via Sutro internal channels. However, regardless of the origin, that massive amount of Sutro data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Sutro Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sutro Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sutro Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sutro Biopharma alpha.
Sutro Biopharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Sutro Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Sutro Biopharma Corporate Management
| Barbara Leyman | Chief Officer | Profile | |
| Shabbir Anik | Chief Technical Operations Officer | Profile | |
| William JD | CEO Director | Profile | |
| Nicki Vasquez | Chief Officer | Profile | |
| Annie MBA | VP Relations | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.51) | Revenue Per Share | Quarterly Revenue Growth (0.50) | Return On Assets | Return On Equity |
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Sutro Biopharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.